-
Mashup Score: 0Could Everolimus Offer a New Treatment Option for SDH-Deficient GIST? | Docwire News - 19 day(s) ago
To determine potential efficacious treatments, a recent retrospective analysis sought to identify novel actionable alterations in patients with SDH-deficient GISTs.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
Dr. Dotan shared the effects of baseline geriatric and QOL assessments on outcomes for older patients with pancreatic cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📺 At @ASCO #GI25, Dr. @efratdotan of the Ann B Barshinger Cancer Institute at @LGHealth shared the effects of baseline geriatric and quality of life assessments on treatment outcomes for older patients with metastatic #pancreatic cancer: https://t.co/BzFQ7G7suR https://t.co/juTvOogUhk
-
-
Mashup Score: 4ASCO GI Featured Voice: Dr. Supriya Peshin on Research, Women in Oncology, and More | Docwire News - 22 day(s) ago
At ASCO GI 2025, Supriya Peshin, MD, resident physician at Ballad Health and an ASCO GI Featured Voice, gives her thoughts on the future of GI oncology.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ At @ASCO #GI25, we spoke with @supriyadocc, resident physician at @BalladHealth and an ASCO GI Featured Voice, about her thoughts on the future of GI oncology and the research that she found most interesting at the 2025 conference: https://t.co/9aEMy2aEer https://t.co/GvV2I3BzAv
-
-
Mashup Score: 1
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ The first part of a new roundtable discussion moderated by @NataliyaUboha focused on the multidisciplinary management of #gastroesophageal cancers. ⭐ Dr. Uboha was joined by Drs. Zev Wainberg of @UCLAHealth, @SKamath_MD, and @SunnieSKim: https://t.co/D4KnvPHpxA https://t.co/Xzwrf80ROC
-
-
Mashup Score: 8CheckMate 9DW, 8HW, NEST, and Bot/Bal | Docwire News - 24 day(s) ago
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📺 We spoke with @benweinbergmd while at @ASCO #GI25 on new data from CheckMate 9DW, 8HW, NEST, and more. 👉 Catch up with some of the top studies presented at the conference: https://t.co/CPlcN2f7N3 https://t.co/wQ5pSAiqsc
-
-
Mashup Score: 12NAPOLI 3: UGT1A1*28 Polymorphism, Tolerability in Patients With mPDAC | Docwire News - 25 day(s) ago
Dr. Abdelrahim details the impact of UGT1A1*28 polymorphism on tolerability in patients with mPDAC in the NAPOLI 3 study.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
❇️ At @ASCO #GI25, we spoke with Dr. @MaenAbdelrahim on the impact of UGT1A1*28 in patients with #mPDAC who were treated with #NALIRIFOX during NAPOLI 3. 📺 Does UGT1A1*28 status affect safety or dosing in patients? Watch the full interview to find out: https://t.co/Rq8TnpMV5W https://t.co/PhRVZMBdlT
-
-
Mashup Score: 6KEYFORM-007 Results: Co-Formulated Favezelimab and Pembrolizumab in Metastatic Colorectal Cancer | Docwire News - 25 day(s) ago
The study showed that favezelimab/pembrolizumab did not demonstrate a survival benefit over SOC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
👉 At @ASCO #GI25, new results of the KEYFORM-007 study presented by Dr. Neil Segal of @MSKCancerCenter showed that #favezelimab/#pembrolizumab did not improve OS or PFS compared with SOC for patients with PD-L1–positive MSS/pMMR mCRC: https://t.co/xjnHLMG8xo
-
-
Mashup Score: 5Cytokine-Induced Killer Cells Boost RFS, CSS in HCC in Extended Follow-Up | Docwire News - 29 day(s) ago
A two-part study presented at ASCOGI 2025 assessed a trial’s longer-term outcomes and analyzed the underlying mechanisms of sustained effects of CIK cell treatment in HCC.
Source: docwirenews.comCategories: General Medicine News, GastroenterologyTweet-
🔬 A study presented at @ASCO #GI25 assessed the long-term outcomes of cytokine-induced killer cell treatment in #hepatocellularcarcinoma, including an analysis of immune cells in patients who received adjuvant CIK cell treatment: https://t.co/8aVILyA3Vq
-
-
Mashup Score: 1DEEPER Trial Final Analysis: m-FOLFOXIRI, Cetuximab Boosts PFS, OS in mCRC | Docwire News - 29 day(s) ago
A final analysis of the DEEPER trial presented at ASCO GI 2025 has demonstrated the benefits of m-FOLFOXIRI with cetuximab for patients with metastatic colorectal cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🔬 A final analysis of the DEEPER trial presented at @ASCO #GI25 has demonstrated the benefits of m-FOLFOXIRI with #cetuximab for certain forms of #colorectalcancer. 👀 See how the combination compared to #bevacizumab for this patient population: https://t.co/ljh8tXBso8
-
-
Mashup Score: 12NAPOLI 3: UGT1A1*28 Polymorphism, Tolerability in Patients With mPDAC | Docwire News - 29 day(s) ago
Dr. Abdelrahim details the impact of UGT1A1*28 polymorphism on tolerability in patients with mPDAC in the NAPOLI 3 study.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
❇️ At @ASCO #GI25, we spoke with Dr. @MaenAbdelrahim on the impact of UGT1A1*28 in patients with #mPDAC who were treated with #NALIRIFOX during NAPOLI 3. 📺 Does UGT1A1*28 status affect safety or dosing in patients? Watch the full interview to find out: https://t.co/Rq8TnpMV5W https://t.co/PhRVZMBdlT
-
❓ Could #everolimus offer a new treatment options for SDH-deficient #GIST? 👉 A recent retrospective analysis sought to identify novel actionable alterations in patients with this disease, finding that everolimus may offer a sustained tumor response: https://t.co/Ijlr919Wcw